AAV-Mediated Gene Therapy for Retinal Disorders in Large Animal Models

Abstract

Retinal gene therapy holds great promise for the treatment of inherited and noninherited blinding diseases such as retinitis pigmentosa and age-related macular degeneration. The most widely used vectors for ocular gene delivery are based on adeno-associated virus (AAV) because they elicit minimal immune responses and mediated long-term transgene expression in a variety of retinal cell types. Extensive preclinical evaluation of new strategies in large animal models is key to the development of successful gene-based therapies for the retina. Because of differences in the retinal structures among species and unique structures such as the macula and fovea in the primate retina, nonhuman primates are widely used as preclinical animal models. But the observation of inherited retinal degenerations in dogs, which share a number of clinical and pathologic similarities with humans, has led to the characterization of several canine models for retinal diseases, one of which has already responded successfully to AAV-mediated gene therapy. This article presents a review and detailed discussion of the various large animal models available for the study of AAV-mediated gene-based therapies in the retina.

Phosphodiesterase inhibition induces retinal degeneration, oxidative stress and inflammation in cone-enriched cultures of porcine retina

“…This is why the use of large animal models seems to be critical for the development of retinal rescue strategies (Stieger et al, 2009). Anatomically, the pig eye is remarkably similar to the human eye and it is well-endowed with cones (Gerke et al, 1995) especially, in a large horizontal band extending across the retina covering the optic disc and horizontal meridian (Hendrickson and Hicks, 2002).…”

Restoration of Vision in the pde6β-deficient Dog, a Large Animal Model of Rod-cone Dystrophy

“…29 Indeed, the size and anatomy of the eye in large animals provide a more relevant model than rodents in terms of pathobiology and surgical approaches. Moreover, their longevity enables longterm evaluation of the treatment, which is crucial for pathologies such as PDE6β deficiency that typically progress over decades in humans.…”

Preclinical Safety Evaluation of a Recombinant AAV8 Vector for X-Linked Retinoschisis After Intravitreal Administration in Rabbits

“…The reason for testing a viral vector dose of 2e 11 vg/eye, 10-fold higher than the minimum effective dose, was to assess the potential ocular toxicity of AAV8 with a greater safety margin. Although data on the safety of AAV-mediated gene transfer in animal models have been reported (Stieger et al, 2009), this is the first study to describe the ocular response after the…”